Bellicum Pharmaceuticals ... (BLCM)
0.07
-0.01 (-12.61%)
At close: Mar 04, 2024, 7:59 PM
-12.61% (1D)
| Bid | n/a |
| Market Cap | 778.33K |
| Revenue (ttm) | 1.51M |
| Net Income (ttm) | -21.8M |
| EPS (ttm) | -0.67 |
| PE Ratio (ttm) | -0.11156716417910448 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 6,059 |
| Avg. Volume (20D) | 28,581 |
| Open | 0.08 |
| Previous Close | 0.08 |
| Day's Range | 0.07 - 0.09 |
| 52-Week Range | 0.06 - 1.31 |
| Beta | 1.38 |
About BLCM
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem ce...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 18, 2014
Employees 13
Stock Exchange NASDAQ
Ticker Symbol BLCM
Website https://www.bellicum.com